We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...

Sanofi and Blueprint Medicines have entered into an acquisition agreement under which Sanofi will acquire Blueprint for $129 per share in cash. The agreement also includes a contingent value right ...

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold. This ...